Elisabeth Hofmeister, M.Sc.

Doctoral Student and Junior Research Fellow

Innovation and Entrepreneurship Research

+49 89 24246-579

Areas of Interest:

Innovation Economics, Industrial Organization, Competition Economics, Health Economics

Academic Résumé

Since 04/2022
Postgraduate Studies in Business Research (MBR) at Munich School of Management, LMU Munich

Since 10/2021
Junior Research Fellow and Doctoral Candidate at the Max Planck Institute for Innovation and Competition (Innovation and Entrepreneurship Research)

09/2018 – 09/2021
Master of Science (M.Sc.) in Management & Technology with a major in Chemistry, Technical University of Munich (TUM)

08/2016 – 12/2016
Exchange semester at the University of Hong Kong

09/2014 – 09/2018
Bachelor of Science (B.Sc.) in Management & Technology with a minor in Chemistry, Technical University of Munich (TUM)

Work Experience

Working Student Consulting Services, IQVIA Commercial GmbH & Co. OHG, Munich

Internship Business Development, Fresenius Kabi Asia Pacific Ltd., Hong Kong

Project Study “Forum of the Future”, Deutsches Museum, Munich

09/2018 – 07/2019
Working Student Business Development, InGeneron GmbH, Munich

04/2018 – 07/2018
Internship CFO Office / Global Business Services, Fresenius Kabi Deutschland GmbH, Bad Homburg

10/2017 – 03/2018
Internship Audit Corporate, KPMG AG Wirtschaftsprüfungsgesellschaft, Munich

03/2017 – 05/2017
Project Study “Internationality in Human Resources“, MAN Truck & Bus AG, Munich

08/2015 – 06/2016
Working Student Consulting, ROI Management Consulting AG, München


Since 10/2018
TUM Finance and Accounting Selected Talents (TUMfast)


Discussion Papers

Kim, Daria; Hilty, Reto M.; Hofmeister, Elisabeth; Slowinski, Peter R.; Steinhart, Miriam (2022). CRISPR/Cas Technology and Innovation: Mapping Patent Law Issues, Max Planck Institute for Innovation & Competition Research Paper, No. 22-06.

  • The paper provides a systematic overview of issues arising at the interface between CRISPR/Cas technology and patent law. In particular, it examines aspects related to the patentability of CRISPR/Cas-based methods of genome editing, on the one hand, and access to patented technologies, in view of the expanding CRISPR patent landscape, on the other hand. On the whole, our findings show that the case of CRISPR/Cas technology is prototypical of the policy dilemma in patent law as to how to balance economic incentives of multiple innovators in a cumulative innovation setting. The reviewed technical, legal and economic factors suggest the preconditions for technology underutilisation. While this paper presents the results of the exploratory phase of research, it sets a framework for the further, more targeted interdisciplinary examination of the identified issues.
  • Available at SSRN


Shelved Innovation – Evidence from the Pharmaceutical Industry
Strategy & Innovation Brown Bag, Boston University
Location: Boston, USA

Quantification of Shelved Pharma Projects
Research Seminar, Max Planck Institute for Innovation and Competition
Location: Frauenchiemsee

More Progress on Shelving in Pharma – Updates on Text Analysis and Plan for Further Insights
Research Seminar, Max Planck Institute for Innovation and Competition
Location: Bernried

Einblicke in forschende Unternehmen durch die Betrachtung von Schubladen-Projekten
Symposium „Wissenschaftsforschung im Fokus – Potentiale und neue Perspektiven“, VolkswagenStiftung
Location: Hannover

Creating a Pool of Shelved Pharmaceutical Projects and Related Questions
Research Seminar, Max Planck Institute for Innovation and Competition
Location: Ohlstadt